Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.

Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):25-32. doi: 10.1097/QAI.0000000000000095.

2.

Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.

Bronke C, Palmer NM, Jansen CA, Westerlaken GH, Polstra AM, Reiss P, Bakker M, Miedema F, Tesselaar K, van Baarle D.

J Infect Dis. 2005 Mar 15;191(6):873-80. Epub 2005 Jan 31.

PMID:
15717261
3.

Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).

Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B; AIDS Clinical Trials Group Protocol 360 Study Team.

Clin Infect Dis. 2003 Aug 15;37(4):567-78. Epub 2003 Jul 29.

PMID:
12905142
4.

Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.

Villacres MC, Lacey SF, La Rosa C, Krishnan R, Auge C, Longmate J, Zaia JA, Leedom JM, Diamond DJ.

J Infect Dis. 2001 Aug 1;184(3):256-67. Epub 2001 Jul 10.

PMID:
11443550
5.

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team.

HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.

7.

Cytomegalovirus infection in HIV-infected and uninfected individuals is characterized by circulating regulatory T cells of unconstrained antigenic specificity.

Tovar-Salazar A, Weinberg A.

PLoS One. 2017 Jul 6;12(7):e0180691. doi: 10.1371/journal.pone.0180691. eCollection 2017.

8.
9.

Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery.

Singh KP, Howard JL, Wild SP, Jones SL, Hoy J, Lewin SR.

Clin Immunol. 2007 Aug;124(2):200-6. Epub 2007 Jun 15.

PMID:
17574925
10.

Cytomegalovirus-specific regulatory and effector T cells share TCR clonality--possible relation to repetitive CMV infections.

Schwele S, Fischer AM, Brestrich G, Wlodarski MW, Wagner L, Schmueck M, Roemhild A, Thomas S, Hammer MH, Babel N, Kurtz A, Maciejewski JP, Reinke P, Volk HD.

Am J Transplant. 2012 Mar;12(3):669-81. doi: 10.1111/j.1600-6143.2011.03842.x. Epub 2011 Nov 14.

11.

Progression to CMV end-organ disease in HIV-1-infected individuals despite abundance of highly differentiated CMV-specific CD8+ T-cells.

Bronke C, Westerlaken GH, Miedema F, Tesselaar K, van Baarle D.

Immunol Lett. 2005 Mar 15;97(2):215-24. Epub 2004 Nov 28.

PMID:
15752561
13.

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.

Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM.

Nat Med. 1998 Aug;4(8):953-6.

PMID:
9701250
14.

Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.

Chakraborty A, Mahapatra T, Mahapatra S, Ansari S, Siddhanta S, Banerjee S, Banerjee D, Sarkar RN, Guha SK, Chakraborty N.

PLoS One. 2015 Feb 13;10(2):e0117466. doi: 10.1371/journal.pone.0117466. eCollection 2015.

15.

Diagnostic utility of quantitative plasma cytomegalovirus DNA PCR for cytomegalovirus end-organ diseases in patients with HIV-1 infection.

Mizushima D, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Oka S, Gatanaga H.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):140-6. doi: 10.1097/QAI.0000000000000410.

PMID:
25590268
16.
17.

[The subpopulation CD4(+); CD25(+); Foxp3(+);/CD127(low/-); regulatory T cells in peripheral blood of HIV-infected patients correlated with disease progression].

Chen YL, Chen XR, Qin LX, Yang YF, Tang YM.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Nov;28(11):1188-91. Chinese.

PMID:
23127412
18.

Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.

Mizushima D, Nishijima T, Gatanaga H, Tsukada K, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2013 May 28;8(5):e65348. doi: 10.1371/journal.pone.0065348. Print 2013.

19.

CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro.

Kinter AL, Horak R, Sion M, Riggin L, McNally J, Lin Y, Jackson R, O'shea A, Roby G, Kovacs C, Connors M, Migueles SA, Fauci AS.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):438-50.

PMID:
17411377
20.

Regulatory/effector T-cell ratio is reduced in coronary artery disease.

Emoto T, Sasaki N, Yamashita T, Kasahara K, Yodoi K, Sasaki Y, Matsumoto T, Mizoguchi T, Hirata K.

Circ J. 2014;78(12):2935-41. Epub 2014 Oct 18.

Supplemental Content

Support Center